Related Experiment Videos
Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy
T D Alden1, D D Pittman, E J Beres
1Department of Neurosurgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Journal of Neurosurgery
|July 21, 1999
Summary
Direct injection of adenoviral bone morphogenetic protein-2 (BMP-2) gene successfully induced spinal fusion in rats. This gene therapy approach shows promise for future neurosurgical applications in promoting bone formation.
Area of Science:
- Neurosurgery
- Gene Therapy
- Orthopedics
Background:
- Bone morphogenetic protein-2 (BMP-2) is a glycoprotein known to induce bone formation.
- Previous studies confirm BMP-2 protein's efficacy in enhancing spinal fusion.
- Gene therapy offers potential novel applications in neurosurgical procedures.
Purpose of the Study:
- To investigate the efficacy of direct adenoviral gene delivery of BMP-2 for spinal fusion.
- To determine if an adenoviral construct containing the BMP-2 gene can induce bone formation in vivo for spinal fusion.
Main Methods:
- Twelve athymic nude rats were divided into three groups.
- Groups received bilateral or unilateral injections of Ad-BMP-2 (adenovirus with BMP-2 gene) or Ad-beta-gal (control).
- Injections were administered percutaneously and paraspinally at the lumbosacral junction, followed by CT scans and histological analysis at 12 weeks.
Main Results:
- Ectopic bone formation was observed in all rats treated with Ad-BMP-2.
- Bone formation was confirmed via CT scans and histological examination.
- Histological analysis revealed bone at various maturity stages adjacent to spinal processes.
Conclusions:
- Direct injection of adenoviral constructs carrying the BMP-2 gene can induce in vivo endochondral bone formation.
- This gene therapy method shows potential for future spinal fusion applications in neurosurgery.